These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741 [TBL] [Abstract][Full Text] [Related]
4. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Kuriyama A; Endo K Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005 [TBL] [Abstract][Full Text] [Related]
5. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164 [TBL] [Abstract][Full Text] [Related]
6. Herbal medicines and chemotherapy induced peripheral neuropathy (CIPN): A critical literature review. Schloss J; Colosimo M; Vitetta L Crit Rev Food Sci Nutr; 2017 Apr; 57(6):1107-1118. PubMed ID: 25849070 [TBL] [Abstract][Full Text] [Related]
7. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data. Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081 [TBL] [Abstract][Full Text] [Related]
8. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN). Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis. Gaballah A; Shafik A; Elhusseiny K; Ashraf M Asian Pac J Cancer Prev; 2018 Aug; 19(8):2223-2227. PubMed ID: 30139229 [TBL] [Abstract][Full Text] [Related]
10. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Stubblefield MD; McNeely ML; Alfano CM; Mayer DK Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699 [TBL] [Abstract][Full Text] [Related]
11. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials. Kishimoto S; Oshima N; Rinker M; Krishna MC; Takebe N Eur J Cancer; 2019 Jul; 115():111-119. PubMed ID: 31132741 [TBL] [Abstract][Full Text] [Related]
12. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP. Streckmann F; Balke M; Lehmann HC; Rustler V; Koliamitra C; Elter T; Hallek M; Leitzmann M; Steinmetz T; Heinen P; Baumann FT; Bloch W BMC Cancer; 2018 Jan; 18(1):62. PubMed ID: 29316888 [TBL] [Abstract][Full Text] [Related]
13. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. Griffith KA; Merkies IS; Hill EE; Cornblath DR J Peripher Nerv Syst; 2010 Dec; 15(4):314-25. PubMed ID: 21199103 [TBL] [Abstract][Full Text] [Related]
15. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy. Knoerl R; Weller E; Halpenny B; Berry D BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351 [TBL] [Abstract][Full Text] [Related]
16. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Tofthagen CS; McMillan SC; Kip KE Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561 [TBL] [Abstract][Full Text] [Related]
18. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227 [TBL] [Abstract][Full Text] [Related]
19. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C Qual Life Res; 2022 Nov; 31(11):3091-3107. PubMed ID: 35596913 [TBL] [Abstract][Full Text] [Related]
20. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]